Arrowhead Pharmaceuticals Inc (ARWR) - News Archive

Arrowhead Pharmaceuticals Expands Talent Pool with Strategic Inducement Grants Under NASDAQ Regulations In a significant move to bolster its workforce and enhance its competitive edge, Arrowhead Pharmaceuticals, Inc. (N...

In the ever-evolving landscape of pharmaceutical innovation, partnerships can significantly influence a company’s trajectory, particularly for those involved in cutting-edge therapies such as RNA interference (RNAi). Ar...

Arrowhead Pharmaceuticals Advances Pioneering RNA Interference Therapies Across Multiple Fronts Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), headquartered in Pasadena, California, continues to spearhead innovative th...

CSIMarket.com PASADENA, Calif. In an exciting development for the biotechnology landscape, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced a global licensing and collaboration agreement with Novartis aimed...

Arrowhead Pharmaceuticals and Sarepta Therapeutics: Collaborating with Confidence Amid Market Dynamics In the intricate landscape of pharmaceutical collaborations, the relationship between Arrowhead Pharmaceuticals Inc....

Arrowhead Pharmaceuticals, a leading biotechnology company based in Pasadena, California, has recently generated significant excitement in the pharmaceutical industry with two major announcements concerning its investig...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently made significant strides in the development of its investigational drug, plozasiran, for the treatment of familial chylomicronemia syndrome (FCS), a severe and rar...

Arrowhead Pharmaceuticals Enters Global License and Collaboration Agreement with Sarepta Therapeutics PASADENA, Calif. In a noteworthy development in the biotechnology sector, Arrowhead Pharmaceuticals, Inc. (NASDAQ: AR...

Arrowhead Pharmaceuticals Unveils Groundbreaking Data on Plozasiran at AHA24PASADENA, Calif. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has taken center stage at the American Heart Association Scientific Sessions 20...

Raising Awareness and Inspiring Hope: Arrowhead Pharmaceuticals New Campaign on Familial Chylomicronemia Syndrome Familial Chylomicronemia Syndrome (FCS) is a rare and debilitating metabolic disorder characterized by ex...

Arrowhead Pharmaceuticals Inc. recently announced its inducement grants under NASDAQ Listing Rule 5635(c)(4), drawing attention to its financial status as the company navigates through a tumultuous year. During the twel...

In the year of our Lord eighteen hundred and sixty, the learned men and women of science began to unravel the mysteries of the human body, propelling forward the boundless journey toward the alleviation of maladies that...

In a significant breakthrough for patients suffering from familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) unveiled promising results from its pivotal Phase 3 PALISADE study at the...

PASADENA, Calif. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) unveiled promising new data from their Phase 3 PALISADE study of plozasiran, an investigational treatment for familial chylomicronemia syndrome (FCS), duri...

Arrowhead Pharmaceuticals Advances RNAi Therapeutics: New Phase 3 Data, Obesity Candidates, and Strategic FinancingArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) continues to drive innovation in the realm of RNA interfe...

: Arrowhead Pharmaceuticals, a leading innovator in RNA interference (RNAi) technology, is poised to make significant strides in the battle against obesity and metabolic diseases. With its plans to advance two novel can...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), based in Pasadena, California, has announced its intent to advance two promising RNA interference (RNAi)-based candidates, ARO-INHBE and ARO-ALK7, into clinical trials for...

Arrowhead Pharmaceuticals Secures $500 Million Financing and Expands Workforce with New Inducement Grants Arrowhead Pharmaceuticals, Inc., a trailblazer in the field of RNA interference (RNAi) therapeutics, has made sig...

Inducement Grants Approved for New EmployeesArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company, has made a significant move in retaining and attracting top-tier talent by offering induce...

In a strategic move to bolster its workforce, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has recently unveiled its plans to enhance employee engagement through inducement grants. On July 25, 2024, the company s Boar...